BusinessActinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsBy Nasdaq OMXFeb 28, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research ProgramsBy Nasdaq OMXJan 8, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic MutationsBy Nasdaq OMXDec 5, 2017, 12:30 PM UTC
BusinessGlobal Myelodysplastic Syndrome Treatment Market to Surpass US$ 5,742.7 million by 2025By Nasdaq OMXSep 25, 2017, 1:44 PM UTC
